Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis

Clinical and Experimental Immunology

Volumn 174, Issue 3, 2013, Pages 364-371

  Tanaka, H ^a,d   Yang, G X ^a   Iwakoshi, N ^c   Knechtle, S J ^c   Kawata, K ^e   Tsuneyama, K ^a,f   Leung, P ^a   Coppel, R L ^g   Ansari, A A ^c   Joh, T ^d   Bowlus, C ^b   Gershwin, M E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TOYAMA   (Japan)

^g MONASH UNIVERSITY   (Australia)

Author keywords

Anti CD40 ligand antibody; Autoimmunity; Cholangitis; Primary biliary cirrhosis

Indexed keywords

CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BILE DUCT INJURY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CHOLANGITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; HEPATITIS; HISTOPATHOLOGY; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANTI-CD40 LIGAND ANTIBODY; AUTOIMMUNITY; CHOLANGITIS; PRIMARY BILIARY CIRRHOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; ANTIGENS, CD40; AUTOANTIGENS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CD40 LIGAND; CHOLANGITIS; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENOTYPE; LIVER; LIVER CIRRHOSIS, BILIARY; MICE; MICE, INBRED C57BL; MITOCHONDRIA; PROMOTER REGIONS, GENETIC; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 84886312305     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12193     Document Type: Article

References (41)

1. Gershwin ME, Ansari AA, Mackay IR etal. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000; 174:210-225.
2. Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 2008; 47:737-745.
3. Tanaka H, Leung PS, Kenny TP, Gershwin ME, Bowlus CL. Immunological orchestration of liver fibrosis. Clin Rev Allergy Immunol 2012; 43:220-229.
4. Shimoda S, Van de Water J, Ansari A etal. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 1998; 102:1831-1840.
5. Kita H, Lian ZX, Van de Water J etal. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med 2002; 195:113-123.
6. Kita H, Matsumura S, He XS etal. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest 2002; 109:1231-1240.
7. Yang GX, Lian ZX, Chuang YH etal. Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology 2008; 47:1974-1982.
8. Moritoki Y, Zhang W, Tsuneyama K etal. B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology 2009; 136:1037-1047.
9. Feau S, Arens R, Togher S, Schoenberger SP. Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells. Nat Immunol 2011; 12:908-913.
10. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16:111-135.
11. Xu Y, Song G. The role of CD40-CD154 interaction in cell immunoregulation. J Biomed Sci 2004; 11:426-438.
12. Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: the dark side of a great activator. Semin Immunol 2009; 21:293-300.
13. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393:480-483.
14. Ciferska H, Horak P, Hermanova Z etal. The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin Rheumatol 2007; 26:723-728.
15. Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK, Routsias JG. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun 2006; 26:165-171.
16. Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 1999; 42:871-881.
17. Ludwiczek O, Kaser A, Tilg H. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Int J Colorect Dis 2003; 18:142-147.
18. Mayo MJ, Mosby JM, Jeyarajah R etal. The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases. Liver Int 2006; 26:187-196.
19. Afford SC, Ahmed-Choudhury J, Randhawa S etal. CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells. FASEB J 2001; 15:2345-2354.
20. Lleo A, Liao J, Invernizzi P etal. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology 2012; 55:153-160.
21. Oertelt S, Lian ZX, Cheng CM etal. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006; 177:1655-1660.
22. Tsuda M, Zhang W, Yang GX etal. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFbeta receptor type II mice. Hepatology 2013; 57:806-816.
23. Wakabayashi K, Lian ZX, Leung PS etal. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology 2008; 48:531-540.
24. Moritoki Y, Lian ZX, Lindor K etal. B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology 2009; 50:1893-1903.
25. Yoshida K, Yang GX, Zhang W etal. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology 2009; 50:1494-1500.
26. Gerritse K, Laman JD, Noelle RJ etal. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996; 93:2499-2504.
27. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993; 261:1328-1330.
28. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154:1470-1480.
29. Ma J, Xu J, Madaio MP etal. Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses. J Immunol 1996; 157:417-426.
30. Tan J, Town T, Crawford F etal. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 2002; 5:1288-1293.
31. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12:171-181.
32. Leung PS, Iwayama T, Coppel RL, Gershwin ME. Site-directed mutagenesis of lysine within the immunodominant autoepitope of PDC-E2. Hepatology 1990; 12:1321-1328.
33. Brennan FR, Morton LD, Spindeldreher S etal. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. mAbs 2010; 2:233-255.
34. Chung CH, Mirakhur B, Chan E etal. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1, 3-galactose. N Engl J Med 2008; 358:1109-1117.
35. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010; 38:82-89.
36. Selmi C, Meroni PL, Gershwin ME. Primary biliary cirrhosis and Sjogren's syndrome: autoimmune epithelitis. J Autoimmun 2012; 39:34-42.
37. Zhang W, Ono Y, Miyamura Y, Bowlus CL, Gershwin ME, Maverakis E. T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. J Autoimmun 2011; 37:71-78.
38. Wang Q, Selmi C, Zhou X etal. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun 2013; 41:140-145.
39. You Z, Wang Q, Bian Z etal. The immunopathology of liver granulomas in primary biliary cirrhosis. J Autoimmun 2012; 39:216-221.
40. Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black×New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996; 157:3159-3164.
41. Quezada SA, Eckert M, Adeyi OA, Schned AR, Noelle RJ, Burns CM. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum 2003; 48:2541-2554.